BioCentury | Jun 27, 2020
Regulation

Boxed warning on Zogenix’s Dravet syndrome therapy could hamper market prospects

FDA’s approval of a resubmitted NDA for Fintepla to treat seizures associated with Dravet syndrome sets Zogenix up to compete with GW’s Epidiolex in the rare epilepsy market, but the drug’s prospects may be hampered...
BioCentury | Apr 25, 2020
Translation in Brief

Molecular Partners’ trifunctional COVID-19 therapeutic; plus F-star, Inscopix and Ocean Biomedical

Trifunctional fusion protein for COVID-19  Molecular Partners AG (SIX:MOLN) is using its designed ankyrin repeat protein (DARPin) platform to develop a trifunctional SARS-CoV-2 S protein inhibitor. In collaboration with the Swiss Federal Office for Civil...
BC Extra | Jan 11, 2020
Company News

Management Tracks: Wave CFO departs; plus Polaris, Turning Point, ADC, Relmada, Aravive, Affimed, Impel, Candel and more

Wave Life Sciences Ltd. (NASDAQ:WVE) disclosed in an SEC filing that CFO Keith Regnante stepped down to pursue other opportunities. VP and Corporate Controller David Gaiero will serve as interim CFO, principal accounting officer and...
BC Extra | Nov 22, 2019
Financial News

Follow-on roundup: Karuna, CRISPR, Molecular Therapeutics, OptiNose

Since market close on Wednesday, Karuna, CRISPR Therapeutics, Molecular Therapeutics and OptiNose have raised an aggregate of more than $600 million in follow-ons. Karuna Therapeutics Inc. (NASDAQ:KRTX) raised $250 million late Wednesday through the sale...
BC Extra | Sep 9, 2019
Company News

Sept. 9 Company Quick Takes: Alexion licenses Japanese rights to Eidos candidate; plus Molecular Partners-Allergan, Horizon, Alnylam

Alexion gets Japanese rights to BridgeBio's ATTR therapy  The Eidos Therapeutics Inc. (NASDAQ:EIDX) subsidiary of BridgeBio Pharma Inc. (NASDAQ:BBIO) granted Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) exclusive rights to develop and commercialize transthyretin-mediated amyloidosis (ATTR) candidate AG10...
BC Extra | Aug 10, 2019
Company News

Management tracks: Melinta, Editas, Accelerate, Santhera

John Johnson has resigned as CEO of Melinta Therapeutics Inc. (NASDAQ:MLNT). He will stay with the antibiotics company during the search for his successor. David Gill, a board member, was named chairman, replacing Kevin Ferro,...
BC Extra | Aug 6, 2019
Company News

Aug. 6 Company Quick Takes: Sales updates from Alnylam, Sage, Regeneron and GW; plus regulatory updates from MorphoSys and more

Alnylam's Onpattro bests consensus  Sales of amyloidosis therapy Onpattro patisiran from Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) reached $38.2 million in 2Q19, the drug's third full quarter on the market. The figure beat analysts' consensus of $32...
BC Innovations | Jul 11, 2019
Targets & Mechanisms

The tumor stroma rises as the newest source of immuno-oncology targets

With a spate of therapies entering the clinic, the next frontier in the fight against resistance to checkpoint inhibitors will be the stroma. The lead target marks a resurgence of interest in TGFβ, and behind...
BC Extra | Jun 11, 2019
Company News

Management Tracks: Agios’ Biller to retire as CSO; plus Vectura, Molecular Partners, F-star and more

Agios Pharmaceuticals Inc. (NASDAQ:AGIO) said CSO Scott Biller will retire at year end. The cellular metabolism company is searching for a successor. Vectura Group plc (LSE:VEC) said CFO Paul Fry will serve as interim CEO...
BC Innovations | May 28, 2019
Distillery Therapeutics

Inhibition of VEGF-A, P2RX7 or the combination of FLT1 and VEGFR-2 to treat tuberculosis

DISEASE CATEGORY: Infectious disease INDICATION: Tuberculosis Mouse studies suggest inhibiting VEGF-A, P2RX7 or the combination of FLT1 and VEGFR-2 could help treat tuberculosis (TB). In a mouse model of TB, expression of mutant VEGF-A with...
Items per page:
1 - 10 of 98
BioCentury | Jun 27, 2020
Regulation

Boxed warning on Zogenix’s Dravet syndrome therapy could hamper market prospects

FDA’s approval of a resubmitted NDA for Fintepla to treat seizures associated with Dravet syndrome sets Zogenix up to compete with GW’s Epidiolex in the rare epilepsy market, but the drug’s prospects may be hampered...
BioCentury | Apr 25, 2020
Translation in Brief

Molecular Partners’ trifunctional COVID-19 therapeutic; plus F-star, Inscopix and Ocean Biomedical

Trifunctional fusion protein for COVID-19  Molecular Partners AG (SIX:MOLN) is using its designed ankyrin repeat protein (DARPin) platform to develop a trifunctional SARS-CoV-2 S protein inhibitor. In collaboration with the Swiss Federal Office for Civil...
BC Extra | Jan 11, 2020
Company News

Management Tracks: Wave CFO departs; plus Polaris, Turning Point, ADC, Relmada, Aravive, Affimed, Impel, Candel and more

Wave Life Sciences Ltd. (NASDAQ:WVE) disclosed in an SEC filing that CFO Keith Regnante stepped down to pursue other opportunities. VP and Corporate Controller David Gaiero will serve as interim CFO, principal accounting officer and...
BC Extra | Nov 22, 2019
Financial News

Follow-on roundup: Karuna, CRISPR, Molecular Therapeutics, OptiNose

Since market close on Wednesday, Karuna, CRISPR Therapeutics, Molecular Therapeutics and OptiNose have raised an aggregate of more than $600 million in follow-ons. Karuna Therapeutics Inc. (NASDAQ:KRTX) raised $250 million late Wednesday through the sale...
BC Extra | Sep 9, 2019
Company News

Sept. 9 Company Quick Takes: Alexion licenses Japanese rights to Eidos candidate; plus Molecular Partners-Allergan, Horizon, Alnylam

Alexion gets Japanese rights to BridgeBio's ATTR therapy  The Eidos Therapeutics Inc. (NASDAQ:EIDX) subsidiary of BridgeBio Pharma Inc. (NASDAQ:BBIO) granted Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) exclusive rights to develop and commercialize transthyretin-mediated amyloidosis (ATTR) candidate AG10...
BC Extra | Aug 10, 2019
Company News

Management tracks: Melinta, Editas, Accelerate, Santhera

John Johnson has resigned as CEO of Melinta Therapeutics Inc. (NASDAQ:MLNT). He will stay with the antibiotics company during the search for his successor. David Gill, a board member, was named chairman, replacing Kevin Ferro,...
BC Extra | Aug 6, 2019
Company News

Aug. 6 Company Quick Takes: Sales updates from Alnylam, Sage, Regeneron and GW; plus regulatory updates from MorphoSys and more

Alnylam's Onpattro bests consensus  Sales of amyloidosis therapy Onpattro patisiran from Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) reached $38.2 million in 2Q19, the drug's third full quarter on the market. The figure beat analysts' consensus of $32...
BC Innovations | Jul 11, 2019
Targets & Mechanisms

The tumor stroma rises as the newest source of immuno-oncology targets

With a spate of therapies entering the clinic, the next frontier in the fight against resistance to checkpoint inhibitors will be the stroma. The lead target marks a resurgence of interest in TGFβ, and behind...
BC Extra | Jun 11, 2019
Company News

Management Tracks: Agios’ Biller to retire as CSO; plus Vectura, Molecular Partners, F-star and more

Agios Pharmaceuticals Inc. (NASDAQ:AGIO) said CSO Scott Biller will retire at year end. The cellular metabolism company is searching for a successor. Vectura Group plc (LSE:VEC) said CFO Paul Fry will serve as interim CEO...
BC Innovations | May 28, 2019
Distillery Therapeutics

Inhibition of VEGF-A, P2RX7 or the combination of FLT1 and VEGFR-2 to treat tuberculosis

DISEASE CATEGORY: Infectious disease INDICATION: Tuberculosis Mouse studies suggest inhibiting VEGF-A, P2RX7 or the combination of FLT1 and VEGFR-2 could help treat tuberculosis (TB). In a mouse model of TB, expression of mutant VEGF-A with...
Items per page:
1 - 10 of 98